Skip to main content
. Author manuscript; available in PMC: 2014 Dec 12.
Published in final edited form as: J Pediatr Hematol Oncol. 2014 Aug;36(6):413–418. doi: 10.1097/MPH.0000000000000179

Figure 1. Model of evolution of relapsed disease.

Figure 1

A preleukemic stem cell (LSC, light blue) gives rise to frank ALL (dark blue cells). Intrinsically drug resistant clones (red) may be present at diagnosis at low levels. However, LSCs and other subclones may survive initial treatment and acquire additional lesions that result in acquired drug resistance. Rarely, relapse clone is genetically distinct from that at diagnosis (second malignancy).